Status:
COMPLETED
High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication
Lead Sponsor:
Mahidol University
Collaborating Sponsors:
Takeda Pharmaceuticals International, Inc.
Conditions:
Dyspepsia
Helicobacter-associated Gastritis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to compare the efficacy between 1-day high dose PPI-based triple therapy vs. 10-day sequential therapy for Helicobacter pylori eradication in functional dyspepsia patients...
Detailed Description
Background: Helicobacter pylori (HP) play an important role in the pathogenesis of chronic gastritis, peptic ulcer diseases as well as gastric cancer. Helicobacter pylori eradication is a critical st...
Eligibility Criteria
Inclusion
- Functional dyspepsia patients (Rome III) with rapid urease test positive
- Age ≥ 18 years old
- No history of HP eradication
Exclusion
- Recent use of PPI, H2RA, NSAID, Antibiotics within 2 weeks
- Currently use of anticoagulants or ketoconazole
- C/I for gastric biopsy
- History of gastric surgery
- Comorbidity: ESRD, advanced cirrhosis, AIDS, stroke (bed ridden)
- Pregnancy or lactation
- Allergy to studied drugs
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
118 Patients enrolled
Trial Details
Trial ID
NCT01888237
Start Date
May 1 2013
End Date
September 1 2014
Last Update
April 10 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of gastroenterology, Department of Medicine, Siriraj hospital
Bangkok Noi, Bangkok, Thailand, 10700